UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009160
Receipt number R000010723
Scientific Title Influence on estimated glomerular filtration rate in patients with ischemic heart disease and hyperuricemia medicated by febuxostat.
Date of disclosure of the study information 2012/10/22
Last modified on 2013/12/17 14:15:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Influence on estimated glomerular filtration rate in patients with ischemic heart disease and hyperuricemia medicated by febuxostat.

Acronym

Influence on estimated glomerular filtration rate in patients with ischemic heart disease and hyperuricemia medicated by febuxostat.

Scientific Title

Influence on estimated glomerular filtration rate in patients with ischemic heart disease and hyperuricemia medicated by febuxostat.

Scientific Title:Acronym

Influence on estimated glomerular filtration rate in patients with ischemic heart disease and hyperuricemia medicated by febuxostat.

Region

Japan


Condition

Condition

Ischemic heart disease patients with hyperuricemia

Classification by specialty

Cardiology Endocrinology and Metabolism Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the influence of febuxostat on estimated glomerular filtration rate(eGFR) in patients with ischemic heart disease and hyperuricemia.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Changes of estimated glomerular filtration rate(eGFR) between two groups(
control group and medicated group).

Key secondary outcomes

1)Changes of eGFR between each two groups(control group and medicated group).
2)Changes of uric acid levels,
ratio of achiving less than 6.0mg/dl of uric acid levels,
changes of microalbuminuria/creatinine,
changes of creatinene clearance,
changes of C cystatin levels
3)Death, cardiovascular events(acute myocardial infarction, target vessel revascularization, new onset angina pectoris, congestive heart failure, cerebral infarction)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Control group(nutrition education)

Interventions/Control_2

Febuxostat group(febuxostat+nutrition education)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)7.0mg/dl<uric acid levels<9.0mg/dl
2)Patients with ischemic heart disease
3)30ml/min<eGFR<90ml/min

Key exclusion criteria

1)Patients with severe renal injury
(eGFR<30ml/min)
2)Patients with severe liver injury
3)Patients with severe heart failure
(NYHA Class4)
4)Patients with acute myocardial infarction within three months
5)Ineligible patients for any other reasons

Target sample size

240


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Minoru Yoshiyama

Organization

Osaka City University

Division name

Department of Cardiovascular Medicine

Zip code


Address

1-4-3, Asahimachi, Abeno-ku, Osaka

TEL

06-6645-3801

Email



Public contact

Name of contact person

1st name
Middle name
Last name Yuji Sakanoue

Organization

Higashisumiyoshi Morimoto Hospital

Division name

Department of Cardiovascular Medicine

Zip code


Address

3-2-66, Takaai, Higashisumiyoshi-ku, Osaka

TEL

06-6606-0010

Homepage URL


Email

yujisaka@kcn.ne.jp


Sponsor or person

Institute

Osaka City University Department of Cardiovascular Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東住吉森本病院 循環器内科
Higashisumiyoshi Morimoto Hospital Department of Cardiovascular Medicine


Other administrative information

Date of disclosure of the study information

2012 Year 10 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2012 Year 08 Month 01 Day

Date of IRB


Anticipated trial start date

2012 Year 10 Month 22 Day

Last follow-up date

2015 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 10 Month 22 Day

Last modified on

2013 Year 12 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010723


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name